Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Dec 26, 2022; 14(12): 815-821
Published online Dec 26, 2022. doi: 10.4252/wjsc.v14.i12.815
Published online Dec 26, 2022. doi: 10.4252/wjsc.v14.i12.815
Barriers to mesenchymal stromal cells for low back pain
Bao-Gan Peng, Xiu-Jie Yan, Department of Orthopaedics, The Third Medical Center, General Hospital of the Chinese People’s Liberation Army, Beijing 100039, China
Author contributions: Peng BG and Yan XJ conceived the idea for the manuscript and reviewed the manuscript; Both authors contributed equally.
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bao-Gan Peng, MD, PhD, Professor, Department of Orthopaedics, The Third Medical Center, General Hospital of the Chinese People’s Liberation Army, No. 69 Yongding Road, Beijing 100039, China. pengbaogan@163.com
Received: September 27, 2022
Peer-review started: September 27, 2022
First decision: October 24, 2022
Revised: October 30, 2022
Accepted: November 30, 2022
Article in press: November 30, 2022
Published online: December 26, 2022
Peer-review started: September 27, 2022
First decision: October 24, 2022
Revised: October 30, 2022
Accepted: November 30, 2022
Article in press: November 30, 2022
Published online: December 26, 2022
Core Tip
Core Tip: Intervertebral disc is a highly complex weight-bearing tissue, and its degeneration is a major cause of low back pain. Current mesenchymal stromal cell-based clinical trials are difficult to succeed because the repair only targets the degenerated nucleus pulposus, and the transplanted cells die rapidly.